Optos
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Optos sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Optos: 12 sponsored US clinical trials, 2 recruiting.
Optos sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. The most-studied condition in this pipeline is Retinal Disease, with 2 trials.
Top-decile sponsor footprint
Optos ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
Data Gathering for A10900
NCT07149740
P200TxE Diseased Eye Image Collection
NCT06269666
P200TE US Reference Database Study
NCT05844852
Glaucoma Evaluation With the P200TE
NCT06305481
Optic Disc Photograph Collection Study
NCT05532410
P200TE Agreement and Precision Study
NCT05536401
Data Collection With the P200TE and P200TxE
NCT05615896
Study Comparing the P200TxE and P200DTx
NCT03964831
Navigated OCT Imaging With the P200TxE
NCT04003831
Study Comparing the P200TE and the P200TxE in Glaucoma Patients
NCT03912584
Optos P200TE Agreement and Precision Study
NCT03868462
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
NCT01692938
What is open in the Optos pipeline
2 recruiting of 12 indexed (17% open); 7 completed (58%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Retinal Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Optos: open-pipeline peers nationwide
Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Optos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Optos page
12 registered trials is a research-attention snapshot, not an endorsement of Optos or any single study.
- 2 of Optos's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Retinal Disease is the condition Optos studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Retinal Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Optos pipeline card: 12 registered trials from official public datasets.Report a data error.